Continued Respiratory Therapy Phone: 866-382-0799


How Is Cystic Fibrosis Diagnosed?

Prigi Varghese, MSN, APRN, CPNP-PC

October 11, 2021

Share:

Question

How is cystic fibrosis diagnosed?

Answer

Sweat chloride testing is the gold standard for the diagnosis of Cystic Fibrosis (Figure 5). The sweat test needs to be done in a CF Foundation accredited center, where personnel is trained to obtain a sweat test. It provides a conclusive CF diagnosis by measuring the concentration of salt in a person's sweat. The simple, painless test is the most reliable way to diagnose Cystic Fibrosis. Infants do not sweat much. Sweat glands have to be stimulated by using an electrical current, along with a chemical called pilocarpine. We usually test on two sides. Often it is both forearms. After the stimulation, a plastic coil device the size of a quarter is placed and covered with gauze to collect the sweat. We advise families to keep babies hydrated and wrapped in a blanket to obtain enough sweat for the test.

After the sweat test is completed, how do you interpret the results? Well, 60 is the magic number. Always think 60 in Cystic Fibrosis. Sweats are measured in milliequivalent per liter units. Anything over 60 is a positive indication of Cystic Fibrosis. Sweat tests between 31 and 59 are intermediate and will need to be repeated. If the repeat sweat is also intermediate, we get a CFTR gene test, either with blood or a buccal swab. Any sweat tests below 30 are consistent with normal findings. As with any test, there is a chance for false positives and false negatives. Some conditions that can cause false positives include hypothyroidism, Addison's disease, and malnutrition. I have seen many malnourished patients with elevated sweats, and once their malnutrition is corrected, their sweat will normalize. 

We can also get false negatives if the patient has edema, if the sample was diluted, or if they have milder CF mutations. There are patients with two Cystic Fibrosis mutations of milder severity that can have normal sweat tests. In which case, we follow them annually or every six months to see if they ever develop any signs and symptoms of Cystic Fibrosis.

This Ask the Expert is an edited excerpt from the courseCystic Fibrosis: A Comprehensive Overviewpresented by Prigi Varghese, MSN, APRN, CPNP-PC.


prigi varghese

Prigi Varghese, MSN, APRN, CPNP-PC

Prigi Varghese is a Nurse Practitioner with over 15 years of clinical experience. She received her Bachelor of Science in Nursing in 2004 and her Master of Science in Nursing in 2010 from Texas Woman's University in Dallas, Texas. Currently, she is the CF Program Coordinator & Quality Improvement Coordinator for the Pediatric Cystic Fibrosis Center at Children's Health.

Her dual roles in program development and quality improvement involve care coordination for 300+ pediatric patients, identifying high-risk populations with advocacy for follow-up services and support, department-specific initiatives, and process improvements. Her achievements include the 2016 Excellence and Accountability Cornerstone award for all Advanced Practitioners at Children's Health, the 2018 Quality Care Cornerstone Award, and the 2019 Dallas' Finest Award designated by the North Texas CF Foundation.

She is directly involved in various quality improvement initiatives through the CF Foundation and the CF Learning Network. In addition, she has presented on various topics related to Cystic Fibrosis both regionally and nationally.


Related Courses

Cystic Fibrosis: A Comprehensive Overview
Presented by Prigi Varghese, MSN, APRN, CPNP-PC
Video

Presenter

Prigi Varghese, MSN, APRN, CPNP-PC
Course: #1335Level: Intermediate1 Hour
  'Good refresher, I hadn't heard of the new CFTR modulators, happy to know we have made advancements in therapy'   Read Reviews
Cystic Fibrosis is a complex diagnosis that affects multi-organ systems and requires management and care from a multidisciplinary team. This webinar addresses pathophysiology, diagnosis, management of pulmonary and non-pulmonary symptoms. Current and emerging cystic fibrosis therapies are discussed.

Tobacco Management and Smoking Cessation
Presented by Jessica Fino, EdD, RRT
Video

Presenter

Jessica Fino, EdD, RRT
Course: #1304Level: Introductory1 Hour
  'Easy to follow, great information'   Read Reviews
This course provides a review of the various types of tobacco products and nicotine delivery devices. Additional topics include tobacco cessation and tobacco management strategies for the healthcare provider.

Respiratory Management of Patients With Neuromuscular Weakness Series: Review Recommendations and Best Practice
Presented by Duane Reed, EdD, RRT, RCP
Video

Presenter

Duane Reed, EdD, RRT, RCP
Course: #1827Level: Intermediate1 Hour
  'options and diagnostic tools'   Read Reviews
An essential concern in neuromuscular diseases (NMD) is respiratory failure. This course reviews guidelines and evidenced-based literature on the best practice respiratory management of patients with NMD. It is part of an NMD series but can be viewed as a stand-alone learning experience.

Respiratory Management of Patients with Neuromuscular Weakness Series: Review of the Grading of Recommendations for Assessment, Development, and Evaluations
Presented by Duane Reed, EdD, RRT, RCP
Video

Presenter

Duane Reed, EdD, RRT, RCP
Course: #1846Level: Introductory1 Hour
  'I learned a lot about techniques to use on patients with NMD's'   Read Reviews
Clinical experts comprised a multi-professional panel to conduct a systematic review to address patients with neuromuscular diseases (NMD). A review of evidenced-based grading of recommendations and management of patients with NMD is discussed. It is part of an NMD series but can be viewed as a stand-alone learning experience.

Surviving Acute Respiratory Distress Syndrome (ARDS) From Patient to Patient Engagement
Presented by Eileen Rubin, JD
Video

Presenter

Eileen Rubin, JD
Course: #1343Level: Introductory1 Hour
  'This course put the medical professional into the patient experience, from start to finish, and everything in-between'   Read Reviews
The course introduces an Acute Respiratory Distress Syndrome (ARDS) survivor perspective explaining how education and advocacy of resources positively affect patient-centered care. The course presents current ARDS and COVID-19 evidence and disease impact on managing critically ill patients.

Our site uses cookies to improve your experience. By using our site, you agree to our Privacy Policy.